(Q33989725)

30 July 2017

title

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis (English)

1 reference

primary sclerosing cholangitis

30 July 2017

0 references

ascending cholangitis

0 references

patient

0 references

1 reference

4

Gregory J Gores

1 reference

30 July 2017

Cynthia Levy

1

1 reference

30 July 2017

James Lymp

2

1 reference

30 July 2017

Paul Angulo

3

1 reference

30 July 2017

Nicholas Larusso

5

1 reference

30 July 2017

Keith D Lindor

6

1 reference

30 July 2017

publication date

1 September 2005

1 reference

Digestive Diseases and Sciences

30 July 2017

published in

1 reference

30 July 2017

volume

50

1 reference

30 July 2017

issue

9

1 reference

30 July 2017

page(s)

1734-1740

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-005-2927-8

30 July 2017

exact match

0 references

cites work

The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-005-2927-8

Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential

21 January 2018

1 reference

12 December 2020

Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis

1 reference

12 December 2020

Cholangiocarcinoma complicating primary sclerosing cholangitis

1 reference

12 December 2020

The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis

1 reference

12 December 2020

Primary sclerosing cholangitis: a long-term follow-up study

1 reference

12 December 2020

A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis

1 reference

12 December 2020

Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice

1 reference

12 December 2020

Risk factors for biliary tract carcinogenesis

1 reference

12 December 2020

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

1 reference

12 December 2020

Genes and viruses in hepatobiliary neoplasia

1 reference

12 December 2020

CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis

1 reference

12 December 2020

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

1 reference

12 December 2020

Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study

1 reference

12 December 2020

CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation

1 reference

12 December 2020

Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: an analysis of the serological marker CA 19-9

1 reference

12 December 2020

Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis

1 reference

12 December 2020

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis

1 reference

12 December 2020

Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis

1 reference

12 December 2020

Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

1 reference

12 December 2020

10.1007/S10620-005-2927-8

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1018643037

0 references

1 reference